- Purpose of This Guideline
- Benefits and Risks of ART
- Rationale for Rapid ART Initiation
- Counseling and Education Before Initiating ART
- Protocol for Rapid ART Initiation
- General Principles in Choosing a Regimen for Rapid ART Initiation
- Special Considerations
- All Recommendations
- All Good Practices
- Guideline Updates, Development, and Ratings
- Purpose of This Guideline
- Available ART Regimens
- General Principles in Choosing an Initial ART Regimen
- General Considerations With Initial ART Regimens
- Specific Factors to Consider and Discuss With Patients
- Special Considerations for Comorbid Conditions
- ART-Initiation Laboratory Testing
- ARV Dose Adjustments for Hepatic or Renal Impairment
- All Recommendations
- Guideline Updates, Development, and Ratings
- Purpose and Development of This Guideline
- Rationale for and Efficacy of Injectable ART
- Benefits, Limitations, and Risks of CAB/RPV LA as ART
- Considerations for Implementation of CAB/RPV LA as ART
- Initiation and Maintenance of CAB/RPV LA as ART
- Laboratory Testing and Patient Follow-up
- All Recommendations
- How This Guideline Was Developed
Despite the challenges posed by the COVID-19 pandemic, expeditious initiation of antiretroviral therapy (ART) in people newly diagnosed with HIV remains a high priority and can be accomplished with modest adjustments to the established protocol. This guidance aims to assist primary care providers and other clinicians in adjusting the protocol for implementing rapid ART initiation during the COVID-19 pandemic.
Go to the guidance | Download PDF
- HIV Care Provider Definitions
- All FDA-Approved HIV Medications
- ARV Drug Name Abbreviation Key
- Online Resources for Education, Information, and Services
- Use of Dolutegravir in Individuals of Childbearing Capacity
- GOALS Framework for Sexual History Taking in Primary Care
- Health Equity Competencies for Health Care Providers